Physician

Pathology

Dr. Bonnie L. Kemp, MD

Bonnie L. Kemp practices Pathology. She went to Baylor College of Medicine. She has 1 awards "Top MD". Bonnie Kemp is also a published doctor. She has 44 publication published. The most recent publication is: Bivariate RNA and DNA content analysis in breast carcinoma: biological significance of RNA content. She accepts Medicare payments and is registered with Medicare.gov.

Publications

Florid reactive lymphoid hyperplasia (lymphoma-like lesion) of the uterine cervix.
Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma.
Basal cell nevus syndrome concurrent with adenoid cystic carcinoma of salivary gland.
Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature.
Chromosome 5 aberrations and genetic predisposition to lung cancer.
Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations.
Desmoid tumor of the chest wall.
Localized fibrous tumor of the pleura.
Primary liposarcoma of the mediastinum.
Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors.
The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma.
Carcinoid tumors of the lung and family history of cancer.
Adenocarcinoma of the lung in young patients: the M. D. Anderson experience.
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma.
Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior.
Terminal duct adenocarcinomas of the parotid gland.
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type....
C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers.
Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer.
Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma.
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
Clonal genetic alterations in the lungs of current and former smokers.
N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
Bivariate RNA and DNA content analysis in breast carcinoma: biological significance of RNA content.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.
Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer.
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer.
TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer.

Doctors Specialties

Dermatopathology
Pathology

Accepted Insurances

Awards

Top MD

Education

Mayo School of Graduate Medical Education
Baylor College of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Valencia D. Thomas, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan L. Curry, MD This Doctor is OpenDoctor Recommended.
	Dr. Iftikhar Ahmed, MD
	Dr. Christie J. Finch, MD This Doctor is OpenDoctor Recommended.
	Dr. Kenneth D. Aldape, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Roupen H. Dekmezian, MD This Doctor is OpenDoctor Recommended.
	Dr. Dwayne A. Wolf, MD This Doctor is OpenDoctor Recommended.
	Dr. Reka Szigeti, MD This Doctor is OpenDoctor Recommended.
	Dr. Perumal Thiagarajan, MD This Doctor is OpenDoctor Recommended.
	Dr. Alexander J. Lazar, MD This Doctor is OpenDoctor Recommended.
	Dr. Priyadharsini Nagarajan, MD This Doctor is OpenDoctor Recommended.